Home | About | Donate

NOW Welcomes FDA Decision on Women's HSDD Treatment


NOW Welcomes FDA Decision on Women's HSDD Treatment

National Organization for Women (NOW)

WASHINGTON - The Food and Drug Administration did the right thing by approving the first-ever medical treatment for women’s most common sexual complaint and we hope that other safe and effective treatments will be approved. Hypoactive Sexual Desire Disorder (HSDD) is a serious condition experienced by about ten percent of pre-menopausal women, yet it has taken seven years for this drug, Flibanserin (Addyi), to get the green-light.



Low sex drive among women? Really??? I am 70, and, if anything, I’ve seen mostly the opposite (of course, this is Maui!). Can this be a patriarchal scam to pin the sexual dissatisfaction blame on women? …or get us hooked on yet another dubious pharmaceutical? Read the literature: it might work, after you’ve taken it for at least a year. No, thanks! Improving women’s sex drive is not rocket science. Worship the goddess! #CouncilofMatrons